Previous 10 | Next 10 |
Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN +7.3% ) is up in early trade on double normal volume in reaction to its plan to expand development of PH94B, a rapid-onset neuroactive nasal spray, to include the potential treatment of adjustment disorder related to the stress of t...
VistaGen Therapeutics ( OTC:VTGN ) plans to expand clinical development of PH94B, its rapid-onset neuroactive nasal spray, to include treatment of adjustment disorder due to stressors related to the COVID-19 pandemic. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, Sto...
SOUTH SAN FRANCISCO, Calif. , April 28, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) diseases and disorders with high unmet medical...
VistaGen Therapeutics ( OTC:VTGN ) announces a common stock purchase agreement with Lincoln Park Capital Fund, for up to $10.25M. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
SOUTH SAN FRANCISCO, Calif. , March 25, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and central nervous system (CNS) diseases and disorders with high unmet medical ...
Nano cap VistaGen Therapeutics (NASDAQ: VTGN ) jumps 15% premarket on increased volume in response to positive results from a single-site, 30-subject Phase 2a clinical trial evaluating PH10, a rapid-onset synthetic neurosteroid nasal spray, in patients with major depressive dis...
SOUTH SAN FRANCISCO, Calif. , Feb. 20, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced pos...
Today, we will study why Relmada Therapeutics (RLMD) is an attractive clinical-stage biopharmaceutical pick in 2020. Company overview Relmada Therapeutics is a clinical-stage biotechnology company focused on advancing REL-1017 (d-methadone or dextromethadone) as a rapid-acting oral treat...
VistaGen Therapeutics ( OTC:VTGN ): Q3 GAAP EPS of -$0.15. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SOUTH SAN FRANCISCO, Calif. , Feb. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced financia...
News, Short Squeeze, Breakout and More Instantly...
VistaGen Therapeutics Inc. Company Name:
VTGN Stock Symbol:
NASDAQ Market:
VistaGen Therapeutics Inc. Website:
Vistagen Therapeutics (NASDAQ: VTGN ), a clinical-stage, neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, has received multiple new patent...
Vistagen (Nasdaq: VTGN), a clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced the broadening of its global in...
Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has been recognized by Mental Health America (“MHA”) for its dedication to pr...